ALS News Today

January 15, 2021January 15, 2021

Mexiletine May Lessen Motor Neuron ‘Excitability’ to Ease Cramps, Small Trial Suggests

ALS News Today

Mexiletine, a heart medication used off-label to treat muscle cramps due to amyotrophic lateral sclerosis (ALS), was found to be well-tolerated and to stabilize the “hyperexcitability” of motor neurons in ... Read more

January 14, 2021January 14, 2021

Pooling Imaging Data May Make Multi-center Clinical Trials Easier

ALS News Today

Imaging data of brain inflammation in people with amyotrophic lateral sclerosis (ALS) that is obtained using different tracers and imaging equipment can be combined using a technique called the “pseudo ... Read more

January 13, 2021January 13, 2021

PrimeC Earns Orphan Drug Designation in Europe

ALS News Today

The European Medicines Agency has granted orphan drug designation to PrimeC, an investigational combination therapy for amyotrophic lateral sclerosis (ALS). PrimeC, developed by NeuroSense Therapeutics, also has received orphan drug designation ... Read more

January 12, 2021January 12, 2021

First Patient Enrolled in Pridopidine Arm of the HEALEY ALS Platform Trial

ALS News Today

A pivotal clinical trial evaluating pridopidine for the treatment of amyotrophic lateral sclerosis (ALS) has enrolled its first participant, Prilenia Therapeutics, the medicine’s maker, announced. The Phase 2/3 study, dubbed ... Read more

January 11, 2021January 11, 2021

COVID-19 Safety Measures Announced for Biomarker Study

ALS News Today, COVID-19 News

Mitsubishi Tanabe Pharma America (MTPA) is taking proactive measures to address patient safety in its REFINE-ALS biomarker study during the COVID-19 pandemic. The company announced revisions to the study’s protocol ... Read more

January 8, 2021January 8, 2021

CNM-Au8 May Be Source of Motor Neuron Gains Being Seen in Phase 2 Trial

ALS News Today

Nearly half of all patients in a Phase 2 trial of CNM-Au8, Clene Nanomedicine’s lead candidate for the treatment of amyotrophic lateral sclerosis (ALS), showed improvements in the health and ... Read more

January 7, 2021January 7, 2021

Spinogenix Wins Grant to Advance Testing of Potential Oral Therapy

ALS News Today

Spinogenix has been awarded a research grant from the U.S. Department of Defense (DOD) to further test its lead compound as a potential treatment of amyotrophic lateral sclerosis (ALS), the ... Read more

January 6, 2021January 6, 2021

Human Cell Model Captures Brain and Muscle Interaction for 1st Time

ALS News Today

A system using human cells to model how the brain controls muscle movement has been developed for the first time, and scientists expect it to aid in understanding neurological disorders ... Read more

January 5, 2021January 5, 2021

Extension Study Will Continue Evaluating Oral Edaravone

ALS News Today

Mitsubishi Tanabe Pharma America (MTPA) has launched an extension study to assess the long-term effects of an investigational oral formulation of edaravone (MT-1186) for the treatment of amyotrophic lateral sclerosis ... Read more

January 4, 2021January 5, 2021

4th Potential ALS Therapy, SLS-005, Added to HEALEY Platform Trial

ALS News Today

A Phase 2b/3 trial investigating the potential of SLS-005 (trehalose) to slow the progression of amyotrophic lateral sclerosis (ALS) has been added to the HEALEY ALS Platform Trial, the first such ... Read more

December 21, 2020December 21, 2020

Target ALS Awards 4 Grants for Work Into Biomarker Discovery

ALS News Today

Target ALS, a nonprofit working to advance research, has awarded a second round of grants supporting four projects that aim to discover and develop biomarkers for amyotrophic lateral sclerosis (ALS). ... Read more

December 18, 2020December 18, 2020

ALS Association Cheers Likely End of 5-Month Wait for US Disability Benefits

ALS News Today

After years of behind-the-scenes work, the ALS Association is celebrating passage of the ALS Disability Insurance Access Act of 2019, likely to end the nearly half-year wait amyotrophic lateral sclerosis ... Read more

December 17, 2020December 17, 2020

AstroRx Given at Higher Dose Still Safely Slowing ALS Progression, Trial Reports

ALS News Today

A single infusion of AstroRx, an off-the-shelf, investigational cell therapy for amyotrophic lateral sclerosis (ALS), safely and significantly slows disease progression in the first three months following treatment, according to ... Read more

December 16, 2020December 16, 2020

NurOwn May Be Given to Early ALS Patients in US Who Finished Phase 3 Trial

ALS News Today

BrainStorm Cell Therapeutics has opened an expanded access program (EAP) in the U.S. to allow certain amyotrophic lateral sclerosis (ALS) patients to gain access to its investigational cell-based therapy NurOwn. ... Read more